Finnish Institute to Use Labcyte Tech to Enhance Cancer Testing Studies | GenomeWeb

NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

Helsinki-based FIMM has already used Labcyte's acoustic liquid handling technology to generate better data and to reduce the costs of its small-molecule screening for the past three years, Labcyte CEO Mark Fischer-Colbrie said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.